Iboga compounds reverse the behavioural disinhibiting and corticosterone effects of acute methamphetamine: Implications for their antiaddictive properties.
Karen K. Szumlinski, R E Haskew, M Y Balogun, Isabelle M Maisonneuve, Stanley D Glick
Pharmacology, Biochemistry, and Behavior 2001 DOI: 10.1016/s0091-3057(01)00564-0 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Population | Rats |
| Interventions | Ibogaine 18-methoxycoronaridine |
| Dose | 40 mg/kg ip |
| Duration | 19-hour pretreatment, acute methamphetamine administration 20 minutes before testing |
| Topics | Ibogaine |
| Keywords | Iboga compounds Ibogaine derivatives Iboga alkaloids Stimulant addiction treatment Drug addiction therapy Substance abuse treatment Anti-addiction potential Stimulant reversal Methamphetamine treatment Neuropharmacology Psychopharmacology Behavioral neuroscience Stress response modulation Drug mechanisms Crystal meth |
| Citations | 28 |
| Key findings | Ibogaine and 18-methoxycoronaridine antagonized the behavioral disinhibition and corticosterone increase induced by methamphetamine. |
Abstract
This study investigated the effects of pretreatment with the putative antiaddictive compound, ibogaine (IBO), and its synthetic derivative, 18-methoxycoronaridine (18-MC), on the changes in behaviour in an elevated plus maze and the changes in corticosterone (CORT) produced by a low dose of methamphetamine (METH). In the elevated plus maze, the acute administration of METH (0.1 mg/kg ip, -20 min) produced an increase in both the number and the duration of open arm entries relative to saline (SAL)-treated controls. No effect of METH administration was observed on the total number of arm entries. These data indicated that METH alone produced either anxiolysis or behavioural disinhibition in this paradigm. More consistent with the latter possibility, the open arm behaviour of METH controls was associated with an increase in plasma levels of CORT, supporting a facilitatory role for CORT in this METH-induced effect. Pretreatment with both IBO and 18-MC (40 mg/kg ip, 19 h earlier) antagonized the behavioural disinhibiting effects of acute METH without altering locomotor activity. In addition, both iboga agents antagonized the increase in CORT produced by METH. These data provide insight into yet another potential mechanism through which iboga compounds may exert their antiaddictive effects, a reversal of the behavioural disinhibiting properties of stimulant drugs. Furthermore, these data indicate that this reversal is related to effects of iboga compounds on the stimulation of neuroendocrine systems by stimulant drugs.
Comparable studies
Other preclinical and animal studies on ibogaine, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Noncompetitive Functional Inhibition at Diverse, Human Nicotinic Acetylcholine Receptor Subtypes by Bupropion, Phencyclidine, and Ibogaine TE671/RD cells (human muscle-type nAChR) and SH-SY5Y neuroblastoma cells (human... | 1999 | In vitro study | |
| Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline. Ibogaine- or harmaline-treated rats | 1993 | Experimental animal study | |
| Effects and aftereffects of ibogaine on morphine self-administration in rats. Rats | 1991 | Preclinical experimental study | |
| Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum. Rats | 1994 | Experimental study | |
| Glial Cell Line-Derived Neurotrophic Factor Mediates the Desirable Actions of the Anti-Addiction Drug Ibogaine against Alcohol Consumption Rats | 2005 | Experimental study |
Citations in the library
Cited by 5
- Ibogaine as a treatment for substance misuse: Potential benefits and practical dangers. Progress in Brain Research 2018
- The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology International Journal of Molecular Sciences January 10, 2023
- Hallucinogens: an update. Current Psychiatry Reports October 1, 2003
- The Nonclassic Psychedelic Ibogaine Disrupts Cognitive Maps. Biological Psychiatry Global Open Science 2024
- Behavioral effects of ketamine and toxic interactions with psychostimulants BMC Neuroscience March 16, 2006
Cites 12
- Inhibitory effects of ibogaine on cocaine self-administration in rats. European Journal of Pharmacology September 14, 1993
- Mechanisms of Antiaddictive Actions of Ibogainea. Annals of the New York Academy of Sciences May 1, 1998
- Ibogaine reduces preference for cocaine consumption in C57BL/6By mice. Pharmacology, Biochemistry, and Behavior 1994
- Interactions between ibogaine and cocaine in rats: in vivo microdialysis and motor behavior. European Journal of Pharmacology March 3, 1992
- Interactions of ibogaine and D-amphetamine: in vivo microdialysis and motor behavior in rats. Brain Research May 1, 1992
and 7 more in the library